Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

742
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
742
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

457
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
457
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69
Signs of Puberty01:27

Signs of Puberty

419
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
419
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Menopause01:28

Menopause

200
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

I See the End.

Military medicine·2016
Same author

Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.

ACS medicinal chemistry letters·2016
Same author

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.

Journal of medicinal chemistry·2015
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

788

Hormone Therapy: Testosterone Replacement Therapy.

Lindsay Snow1

  • 1Department of Family and Community Medicine - University of North Dakota School of Medicine and Health Sciences, 1301 N Columbia Rd Stop 9037, Grand Forks ND 58202-9037.

FP Essentials
|August 21, 2023
PubMed
Summary
This summary is machine-generated.

Men with hypogonadism, characterized by low testosterone levels and symptoms, may benefit from testosterone replacement therapy (TRT). Individualized management and monitoring are crucial, with nonhormonal options available.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.2K

Related Experiment Videos

Last Updated: Jul 18, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

788
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.2K

Area of Science:

  • Endocrinology
  • Men's Health

Background:

  • Testosterone levels naturally decline with age.
  • Hypogonadism occurs when testes produce insufficient testosterone.
  • Low testosterone is generally defined as <300-350 ng/dL on two morning samples.

Purpose of the Study:

  • To review the criteria and management of hypogonadism.
  • To discuss testosterone replacement therapy (TRT) options and considerations.
  • To highlight alternative nonhormonal pharmacotherapies.

Main Methods:

  • Review of current guidelines and literature on hypogonadism and TRT.
  • Discussion of diagnostic criteria, including serum testosterone levels and symptoms.
  • Exploration of various TRT formulations and their associated factors.

Main Results:

  • TRT requires confirmed hypogonadism (low testosterone + symptoms).
  • Management is individualized, emphasizing shared decision-making on risks, benefits, and expectations.
  • Available TRT formulations include gels and injections, with choices based on cost and preference.
  • TRT use has limitations including contraindications, side effects, and limited long-term safety data, necessitating close patient monitoring.

Conclusions:

  • Hypogonadism management requires careful patient assessment and individualized treatment plans.
  • Testosterone replacement therapy offers benefits but requires monitoring due to potential risks and limited long-term data.
  • Nonhormonal pharmacotherapies serve as alternatives for specific patient groups.